HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Donaghue, K. C. Articles by Silink, M. Search for Related Content PubMed PubMed Citation Articles by Donaghue, K. C. Articles by Silink, M. Social Bookmarking                What's this?

Do All Prepubertal Years of Diabetes Duration Contribute Equally to Diabetes Complications?

¹ Institute of Paediatric Endocrinology, Diabetes and Metabolism, The Royal Alexandra Hospital for Children, Westmead, Australia
² University of Sydney, Sydney, Australia
³ School of Women’s and Children’s Health, University of New South Wales, Sydney, Australia

	ABSTRACT

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 
OBJECTIVE—This study was designed to explore the timeline of protection against complications in prepubertal children with diabetes, in particular the effects of diabetes duration before age 5 years.

RESEARCH DESIGN AND METHODS—In this study, 193 adolescents with prepubertal diabetes onset were followed longitudinally for retinopathy (early background and clinical) and microalbuminuria (albumin excretion rate >7.5 µg/min and >20 µg/min). Multiple logistic regression analysis was used to compare the effect of pre- and postpubertal diabetes duration on the risk of each complication in 90 subjects reassessed as young adults. For the entire cohort, Kaplan-Meier estimates were used to determine time free of each complication, and survival was compared in those diagnosed before and after age 5 years. Accelerated failure time modeling was used to estimate the effect of covariates, including diabetes duration before puberty, on the risk of complications.

RESULTS—Prepubertal duration improved the prediction for retinopathy over postpubertal duration alone in the young adults. The survival-free period of retinopathy and microalbuminuria was significantly longer (2–4 years) for those diagnosed before age 5 years compared with those diagnosed after age 5 years. Time to onset of all complications increased progressively with longer diabetes duration before gonadarche. Higher HbA_1c during adolescence had an independent effect on the risk of retinopathy and microalbuminuria.

CONCLUSIONS—Prepubertal diabetes duration remains a significant predictor of retinopathy in young adults. The effect of time on the risk of retinopathy and microalbuminuria is nonuniform, with an increasing delay in the onset of complications in those with longer prepubertal duration. These findings are of major clinical importance when setting targets of glycemic control in young children who are at greatest risk of hypoglycemia.

Abbreviations: AER, albumin excretion rate • DCCT, Diabetes Control and Complications Trial • IQR, interquartile range • OR, odds ratio • TR, time ratio

	INTRODUCTION

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 
Parents and health professionals caring for very young children with diabetes must balance the opposing risks of hypoglycemia and future microvascular complications. Although the importance of avoiding severe hypoglycemia in children age <5 years is well documented (1–3), the relative contribution of these prepubertal years to the development of complications remains less certain (4).

In an earlier study using logistic regression, researchers demonstrated that longer prepubertal diabetes duration increased the risk of retinopathy, but not microalbuminuria, in adolescents (5). Studies using survival analysis have also demonstrated that the duration during prepubertal years contributes to retinopathy (6–8), and one study has demonstrated the contribution of prepubertal duration to microalbuminuria (9). Total duration as a continuous variable was not a significant predictor of microalbuminuria in a Norwegian study, but onset of diabetes before age 13 years conferred an increased risk compared to onset after age 13 years (10). In contrast, a recent study assessing urinary albumin concentration in children from the onset of diabetes demonstrated an effect of older age at diagnosis on the incidence of microalbuminuria, after adjusting for duration (11). These findings suggest that the contribution of prepubertal duration may not be uniform.

The current study was designed to explore the timeline of protection against complications in a previously reported cohort with prepubertal-onset diabetes who were followed longitudinally into adulthood. Of particular interest were the effects of diabetes duration before age 5 years and diabetes duration in time intervals before gonadarche. Accelerated failure time modeling was used because of the nonuniform effects of variables over time.

	RESEARCH DESIGN AND METHODS

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 
The study group was the previously reported cohort of 193 adolescents with diabetes (103 boys, 90 girls) whose date of gonadarche (Tanner stage two breasts or testicular volume of 4 ml) was documented in the hospital records as occurring after diabetes onset (5). Of those, 56 adolescents were diagnosed before age 5 years (median age 3.1 [2.2-4.3] years) and 137 were diagnosed after age 5 years (median age 8.4 [6.9–10.1] years). The cohort was followed longitudinally from adolescence to early adulthood. Assessments were performed between 1990 and 2000 at the Royal Alexandra Hospital for Children. The median number of assessments for each subject was three: 63 (33%) had one to two assessments, 65 (34%) had three to four assessments, and 41 (21%) had five to six assessments. At the time of the last assessment, 90 subjects were age >19 years; this group we defined as "young adults." Informed consent was obtained from all participants and the study was approved by the hospital’s Ethics Committee.

Complication assessment
Retinopathy was assessed using stereoscopic fundal photography of seven fields. Early retinopathy was defined as at least one microaneurysm or hemorrhage (grade 21/10 or higher) in one eye. Clinical retinopathy was defined, as in the Diabetes Control and Complications Trial (DCCT) (12), as at least one microaneurysm and one hemorrhage in one eye and at least one microaneurysm or hemorrhage in the other eye (grade 31/21 or higher).

Albumin was measured using a polyclonal radioimmunoassay (Pharmacia AB, Uppsala, Sweden). The mean albumin excretion rate (AER) was calculated from three consecutive timed overnight urine collections. Early elevation of AER was defined as a mean AER 7.5 µg/min (the 95th centile for 690 nondiabetic Australian school children was found to be 7.2 µg/min) (13), and microalbuminuria was defined as an AER 20 µg/min in two of three samples or an albumin/creatinine ratio 2.5 mg/mmol.

HbA_1c was measured at each assessment at a central laboratory using the Bio-Rad Diamat analyzer (Bio-Rad, Hercules, CA). This is a high-performance liquid chromatographic method for measuring HbA_1c as a proportion of total hemoglobin. The nondiabetic range established for this method is 4–6% (mean nondiabetic HbA_1c = 4.99 ± 0.36%).

Statistical analysis
Four outcome variables were used: early and clinical retinopathy, early elevation in AER, and microalbuminuria. Because logistic regression was used in the earlier analysis (5) to investigate the effect of prepubertal diabetes duration of this cohort, we elected to use this method of analysis again in the subgroup of 90 who were now young adults (age >19 years) to allow direct comparison with our previous results. The significance of prepubertal diabetes duration for each complication was examined after adjusting for postpubertal duration and other covariates.

For the entire cohort of 193, the Kaplan-Meier estimate was used to determine median survival time for each complication; 190 had gradable photographs and 168 provided a urine specimen. In a univariate analysis, the log-rank test was used to compare survival between those diagnosed before and after age 5 years. A cutoff of age 5 years was used because those age <5 years are at greatest risk from hypoglycemia (1) and because it allowed for comparison with previous studies (11). Accelerated failure time modeling was used to estimate the effect of covariates on the risk of complications (14). Cox proportional hazards regression modeling was not used because the assumptions underlying this model, in particular that covariates are constant over time, were not met by these data. Diabetes duration was the time variable; the covariates analyzed were sex, HbA_1c, (as a continuous and binary variable, using the median value as a cutoff point), age at diagnosis (before or after age 5 years), three time intervals before gonadarche (diabetes onset 5 years, 2 to <5 years, and <2 years before gonadarche), insulin dosage per kilogram, and number of injections per day (two versus three or more). Nonsignificant variables were excluded from the model. Statistical analysis was performed using STATA, version 6.0, and SPSS, version 10.0.

Results are expressed as medians and interquartile range (IQR). The odds ratio (OR) and 95% CI are reported for logistic regression analysis. The time ratio (TR) and 95% CI are reported for accelerated failure time modeling. The TR is the time to onset of an event, after adjusting for other variables in the model.

	RESULTS

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 
Final assessment as young adults
Data were available on 90 individuals age >19 years (47% of the original cohort). Their median age was 21.7 (20.3–23.7) years and median diabetes duration was 15.6 (12.6–17.9) years. Their median HbA_1c at this final assessment was 8.3% (7.2–9.6%). This group did not differ significantly in age, diabetes duration (pre- or postpubertal), socioeconomic status, previous HbA_1c, or complications status at the time of the previous report (5) from the 103 not reassessed. At this latest time point, early retinopathy was present in 75%; clinical retinopathy in 36% (three had required laser treatment); AER 7.5 µg/min in 41%; and microalbuminuria in 14%.

Using multiple logistic regression and after adjusting for HbA_1c, the risk for clinical retinopathy increased by 28% for every prepubertal year of duration (OR 1.28 [1.08–1.53]) and by 36% for every postpubertal year of diabetes duration (OR 1.36 [1.10–1.69]). Inclusion of prepubertal duration in the model improved the prediction for clinical retinopathy, with all three variables (HbA_1c and pre- and postpubertal duration) together accounting for 14.9% of the variation (r² = 5.8% in the model without prepubertal duration, likelihood ratio test P < 0.001). Age was not significant in the model. Findings were similar for early or clinical retinopathy: prepubertal duration OR 1.25 (1.04–1.49) and postpubertal duration OR 1.45 (1.13–1.86). Only higher HbA_1c (but neither age nor duration) increased the risk for elevated AER (OR 1.42 [1.02–1.97]) and for microalbuminuria (OR 1.36 [1.04–1.78]).

Survival analysis
The median survival time in the 193 subjects was 9.7 (7.7–13.3) years to onset of early retinopathy, 14.9 (12.6–18.7) years for clinical retinopathy, 11.1 years (9.3 - 18.2) for AER 7.5 µg/min, and 21.2 years for microalbuminuria (the IQR could not be defined for microalbuminuria as so few had reached this end point).

The subgroup diagnosed before age 5 years had significantly longer time to onset of the four outcomes compared to those diagnosed after age 5 years (Figs. 1 and 2). The median survival times were 12.2 vs. 8.9 years for retinopathy (P < 0.0001), 15.9 vs. 13.2 years for clinical retinopathy (P = 0.002), and 13.8 vs. 9.5 years for AER 7.5 µg/min (P = 0.0002), respectively. Time to onset of microalbuminuria was significantly longer in those diagnosed before age 5 years (P = 0.02).

View larger version (16K): [in this window] [in a new window]   Figure 1— Survival-free period of any retinopathy and clinical retinopathy in subjects diagnosed before and after age 5 years (log-rank test, P < 0.0001 and P = 0.002, respectively).

View larger version (16K): [in this window] [in a new window]   Figure 2— Survival-free period of AER 7.5 µg/min and microalbuminuria in subjects diagnosed before and after age 5 years (log-rank test, P < 0.0001 and P = 0.0004, respectively).

Effect of diabetes duration before gonadarche.
Time to onset of all four outcomes was significantly longer in subjects with diabetes duration 5 years before gonadarche (Table 1). Time to onset of clinical retinopathy was 39% longer (for any retinopathy, 48% longer) for patients with 5 years compared to those with <2 years of duration before gonadarche. Similarly, time to onset of microalbuminuria was 56% longer (and 81% longer for AER 7.5 µg/min) for patients with 5 years compared to those with <2 years duration before gonadarche. Higher HbA_1c had an independent effect on time to onset of complications: the group with HbA_1c 8.4% had a shorter time to onset of complications by 8–21%.

	CONCLUSIONS

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

In the subgroup of young adults, the continuing significance of prepubertal diabetes duration as a predictor of any retinopathy and clinical retinopathy was confirmed. When examined as adolescents in our earlier study (5), prepubertal duration improved the prediction for retinopathy over postpubertal duration alone. When reexamined as young adults (median duration 15.6 years), the effect of prepubertal duration could now be more adequately compared with that of postpubertal duration. The risk increment for clinical retinopathy was smaller for each year of prepubertal duration compared to each year of postpubertal duration (28 vs. 36%) using logistic regression.

These findings are in agreement with the Berlin Retinopathy Study in which time to onset of retinopathy was compared between patients with pre- and postpubertal onset of diabetes. The median postpubertal duration until incipient retinopathy (defined as 1–10 microaneurysms) was 3 years shorter in those with prepubertal onset diabetes (7). However, incipient retinopathy developed after shorter total diabetes duration in adolescents with pubertal-onset diabetes, indicating that each pubertal year had a greater impact than the prepubertal years (15).

The relative effects of pre- and postpubertal diabetes duration on microalbuminuria could not be compared in the smaller subgroup followed as adults because neither duration was significant in the logistic regression model. However, the relative effects of duration before and after age 5 years were demonstrated using survival analysis in the total group. A significant effect of diabetes duration on the risk of microalbuminuria has been found by some groups (16), but other groups have failed to demonstrate a relation in adolescents (17). In an earlier study of 937 adolescents (18), the authors found that duration accounted for 14% of the variation for clinical retinopathy compared to 6% for microalbuminuria. This indicated that total duration has a smaller effect on the risk of microalbuminura, and that other factors such as HbA_1c (as shown in this study) may be more important.

Any study of complications in adolescents and young adults requires surrogate end points that may be reversible, such as microalbuminuria >20 µg/min (19,20) and clinical retinopathy (21). Because in our study only a small proportion of adolescents or young adults (14%) had reached the end point of microalbuminuria, a mean AER 7.5 µg/min was also used in this analysis. Borderline elevations in AER have been shown to predict progression to persistent microalbuminuria in adults (22,23) and adolescents (24).

Survival analysis explores the time to onset of an end point. Using a cutoff age of 5 years at diagnosis enabled comparison of duration before and after that age on microvascular complications. Comparison of these two groups using the log-rank test demonstrated a significantly longer time to onset of complications (2–4 years) in those diagnosed before age 5 years. This could be explained by the relatively longer prepubertal duration of the individuals diagnosed before age 5 years. Given that we confirmed that postpubertal diabetes duration had a greater effect on retinopathy than prepubertal duration using logistic regression, it was indeed appropriate to use accelerated failure time modeling to account for the nonuniform effects of time.

Accelerated failure time modeling confirmed a significantly longer time to development of complications in the child with diabetes before age 5 years (and the child diagnosed >5 years before onset of his or her gonadarche). The time to onset of complications was longer for children diagnosed at least 5 years before onset of gonadarche compared to diagnosis within 2 years of gonadarche, being 39–48% longer for retinopathy and even longer (56–81%) for elevated AER. Before age 5 years, the gonadal and adrenal axes are relatively inactive, but between age 5 years and the onset of gonadarche, adrenal androgen levels steadily increase (25). However, in an earlier study of prepubertal children ages 8–9 years, the children with early retinopathy actually had significantly lower levels of dehydroepiandrostenedione than those without retinopathy (0.2 vs. 1.1 µmol/l) (26). Growth hormone levels rise after gonadarche onset, and may be the major accelerator of diabetes microvascular disease (27). Therefore, the child with longer diabetes duration before peak growth hormone production is likely to be at lower risk in the prepubertal period.

The current study was the first to quantify the relative risk of different time periods before gonadarche. The longer time seen to onset of AER and microalbuminuria in the young child extends the initial findings from the Joslin Clinic study, in which the later end point of persistent proteinuria was used (28). When subdivided based on age at diagnosis (0–9, 10–14, and 15–20 years), there was a longer time to onset of proteinuria in those with diabetes onset at an earlier age, indicating that prepubertal duration had a lesser effect. In the Oxford Regional Prospective Study, there appeared to be a longer latent period before onset of microalbuminuria in children diagnosed age <5 years compared with those diagnosed at ages 5–11 years and >11 years (11).

HbA_1c at the time of assessment had an independent effect on the risk of microvascular complications after adjusting for diabetes duration. Our data were not intended to explore the effect of prepubertal glycemic control on microvascular disease. However, the model did demonstrate an effect of HbA_1c in pubertal years on the time to complication outcomes that was independent of age at diagnosis (and all were diagnosed before puberty). An elevated HbA_1c during adolescence accelerated the time to onset of complications by 8–21%, whereas a younger age of diagnosis (and longer duration before puberty) slowed the time to onset by 39–81%. This observation is of particular clinical relevance for those caring for children and adolescents. It complements the DCCT finding that intervening to improve diabetes control reduces the risk of complications independently of previous glycemic control (12).

This study confirms that the prepubertal years of diabetes duration are significant for the development of retinopathy. However, the time taken to develop any of the microvascular end points was significantly longer for prepubertal children diagnosed before age 5 years compared to those diagnosed after that age. This implies a greater degree of protection from later microvascular complications in the very young child. These findings are of major clinical importance for management goals of metabolic control given the risks of hypoglycemia in very young children.

	Acknowledgments

 
The authors wish to acknowledge the contributions of Janine Cusumano, RN, and Mandy Crocker, RN, who performed the retinal photography.

	Footnotes

 
Address correspondence and reprint requests to Dr. Kim C. Donaghue, Institute of Paediatric Endocrinology, Diabetes and Metabolism, The Children’s Hospital at Westmead, Locked Bag 4001, NSW 2145, Australia. E-mail: kimd{at}chw.edu.au.

Received for publication 22 July 2002 and accepted in revised form 24 November 2002.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

See accompanying editorial, p. 1304.

	References

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 

1. Ryan C, Vega A, Drash A: Cognitive deficits in adolescents who developed diabetes early in life. Pediatrics 75:921–927, 1985[Abstract/Free Full Text]
   
2. Rovet J, Alvarez M: Attentional functioning in children and adolescents with IDDM. Diabetes Care 20:803–810, 1997[Abstract]
   
3. Craig ME, Handelsman P, Donaghue KC, Chan A, Blades B, Laina R, Bradford D, Middlehurst A, Ambler G, Verge CF, Crock P, Moore P, Silink M: Predictors of glycaemic control and hypoglycaemia in children and adolescents with type 1 diabetes from NSW and the ACT. Med J Aust 177:235–238, 2002[Medline]
   
4. Kostraba JN, Dorman JS, Orchard TJ, Becker DJ, Ohki Y, Ellis D, Doft BH, Lobes LA, LaPorte RE, Drash AL: Contribution of diabetes duration before puberty to development of microvascular complications in IDDM subjects. Diabetes Care 12:686–693, 1989[Abstract]
   
5. Donaghue KC, Fung AT, Hing S, Fairchild J, King J, Chan A, Howard NJ, Silink M: The effect of prepubertal diabetes duration on diabetes: microvascular complications in early and late adolescence. Diabetes Care 20:77–80, 1997[Abstract]
   
6. McNally PG, Raymond NT, Swift PG, Hearnshaw JR, Burden AC: Does the prepubertal duration of diabetes influence the onset of microvascular complications? Diabet Med 10:906–908, 1993[Medline]
   
7. Burger W, Hovener G, Dusterhus R, Hartmann R, Weber B: Prevalence and development of retinopathy in children and adolescents with type 1 (insulin-dependent) diabetes mellitus: a longitudinal study. Diabetologia 29:17–22, 1986[Medline]
   
8. Holl RW, Lang GE, Grabert M, Heinze E, Lang GK, Debatin KM: Diabetic retinopathy in pediatric patients with type-1 diabetes: effect of diabetes duration, prepubertal and pubertal onset of diabetes, and metabolic control. J Pediatr 132:790–794, 1998[Medline]
   
9. Holl RW, Grabert M, Thon A, Heinze E: Urinary excretion of albumin in adolescents with type 1 diabetes. Diabetes Care 22:1555–1560, 1999[Abstract/Free Full Text]
   
10. Joner G, Brinchmann-Hansen O, Torres CG, Hanssen KF: A nationwide cross-sectional study of retinopathy and microalbuminuria in young Norwegian type 1 (insulin-dependent) diabetic patients. Diabetologia 35:1049–1054, 1992[Medline]
    
11. Schultz CJ, Konopelska-Bahu T, Dalton RN, Carroll TA, Stratton I, Gale EA, Neil A, Dunger DB: Microalbuminuria prevalence varies with age, sex, and puberty in children with type 1 diabetes followed from diagnosis in a longitudinal study: Oxford Regional Prospective Study Group. Diabetes Care 22:495–502, 1999[Abstract]
    
12. DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986, 1993[Abstract/Free Full Text]
    
13. Couper JJ, Staples AJ, Cocciolone R, Nairn J, Badcock N, Henning P: Relationship of smoking and albuminuria in children with insulin-dependent diabetes. Diabet Med 11:666–669, 1994[Medline]
    
14. Wei LJ: The accelerated failure time model: a useful alternative to the Cox regression model in survival analysis. Stat Med 11:1871–1879, 1992[Medline]
    
15. Danne T, Kordonouri O, Hovener G, Weber B: Diabetic angiopathy in children. Diabet Med 14:1012–1025, 1997[Medline]
    
16. Jones CA, Leese GP, Kerr S, Bestwick K, Isherwood DI, Vora JP, Hughes DA, Smith C: Development and progression of microalbuminuria in a clinic sample of patients with insulin dependent diabetes mellitus. Arch Dis Child 78:518–523, 1998[Abstract/Free Full Text]
    
17. Cook JJ, Daneman D: Microalbuminuria in adolescents with insulin-dependent diabetes mellitus. Arch Pediatr Adolesc Med 144:234–237, 1990[Abstract]
    
18. Donaghue KC, Fairchild JM, Chan A, Hing SJ, Howard NJ, Silink M: Diabetes complication screening in 937 children and adolescents. J Pediatr Endocrinol Metab 12:185–192, 1999[Medline]
    
19. Rudberg S, Dahlquist G: Determinants of progression of microalbuminuria in adolescents with IDDM. Diabetes Care 19:369–371, 1996[Abstract]
    
20. Gorman D, Sochett E, Daneman D: The natural history of microalbuminuria in adolescents with type 1 diabetes. J Pediatr 134:333–337, 1999[Medline]
    
21. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 107:237–243, 1989[Abstract]
    
22. Chase HP, Marshall G, Garg SK, Harris S, Osberg I: Borderline increases in albumin excretion rate and the relation to glycemic control in subjects with type I diabetes. Clin Chem 37:2048–2052, 1991[Abstract/Free Full Text]
    
23. Gilbert RE, Tsalamandris C, Bach LA, Panagiotopoulos S, O’Brien RC, Allen TJ, Goodall I, Young V, Seeman E, Murray RM: Long-term glycemic control and the rate of progression of early diabetic kidney disease. Kidney Int 44:855–859, 1993[Medline]
    
24. Couper JJ, Clarke CF, Byrne GC, Jones TW, Donaghue KC, Nairn J, Boyce D, Russell M, Stephens M, Raymond J, Bates DJ, McCaul K: Progression of borderline increases in albuminuria in adolescents with insulin-dependent diabetes mellitus. Diabet Med 14:766–771, 1997[Medline]
    
25. Korth-Schutz S, Levine LS, New MI: Serum androgens in normal prepubertal and pubertal children and in children with precocious adrenarche. J Clin Endocrinol Metab 42:117–124, 1976[Abstract]
    
26. Donaghue KC, Fairchild JM, Chan A, Hing SJ, King J, Howard NJ, Silink M: Diabetes microvascular complications in prepubertal children. J Pediatr Endocrinol Metab 10:579–585, 1997[Medline]
    
27. Albertsson-Wikland K, Rosberg S, Karlberg J, Groth T: Analysis of 24-hour growth hormone profiles in healthy boys and girls of normal stature: relation to puberty. J Clin Endocrinol Metab 78:1195–1201, 1994[Abstract]
    
28. Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR: The changing natural history of nephropathy in type I diabetes. Am J Med 78:785–794, 1985[Medline]
    

CiteULike

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				A. Galler, G. Gelbrich, J. Kratzsch, N. Noack, T. Kapellen, and W. Kiess Elevated serum levels of adiponectin in children, adolescents and young adults with type 1 diabetes and the impact of age, gender, body mass index and metabolic control: a longitudinal study Eur. J. Endocrinol., October 1, 2007; 157(4): 481 - 489. [Abstract] [Full Text] [PDF]

				K. Raile, A. Galler, S. Hofer, A. Herbst, D. Dunstheimer, P. Busch, and R. W. Holl Diabetic Nephropathy in 27,805 Children, Adolescents, and Adults With Type 1 Diabetes: Effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset, and sex Diabetes Care, October 1, 2007; 30(10): 2523 - 2528. [Abstract] [Full Text] [PDF]

				M. L. Stone, M. E. Craig, A. K. Chan, J. W. Lee, C. F. Verge, and K. C. Donaghue Natural History and Risk Factors for Microalbuminuria in Adolescents With Type 1 Diabetes: A longitudinal study. Diabetes Care, September 1, 2006; 29(9): 2072 - 2077. [Abstract] [Full Text] [PDF]

				M. C. Eppens, M. E. Craig, J. Cusumano, S. Hing, A. K.F. Chan, N. J. Howard, M. Silink, and K. C. Donaghue Prevalence of Diabetes Complications in Adolescents With Type 2 Compared With Type 1 Diabetes. Diabetes Care, June 1, 2006; 29(6): 1300 - 1306. [Abstract] [Full Text] [PDF]

				M. Svensson, L. Nystrom, S. Schon, G. Dahlquist, and on behalf of the Swedish Childhood Diabetes Study Age at Onset of Childhood-Onset Type 1 Diabetes and the Development of End-Stage Renal Disease: A nationwide population-based study. Diabetes Care, March 1, 2006; 29(3): 538 - 542. [Abstract] [Full Text] [PDF]

				P. Finne, A. Reunanen, S. Stenman, P.-H. Groop, and C. Gronhagen-Riska Incidence of End-stage Renal Disease in Patients With Type 1 Diabetes JAMA, October 12, 2005; 294(14): 1782 - 1787. [Abstract] [Full Text] [PDF]

				S. J. Glastras, M. E. Craig, C. F. Verge, A. K. Chan, J. M. Cusumano, and K. C. Donaghue The Role of Autoimmunity at Diagnosis of Type 1 Diabetes in the Development of Thyroid and Celiac Disease and Microvascular Complications Diabetes Care, September 1, 2005; 28(9): 2170 - 2175. [Abstract] [Full Text] [PDF]

				F. Mohsin, M. E Craig, J. Cusumano, A. K.F. Chan, S. Hing, J. W. Lee, M. Silink, N. J. Howard, and K. C. Donaghue Discordant Trends in Microvascular Complications in Adolescents With Type 1 Diabetes From 1990 to 2002 Diabetes Care, August 1, 2005; 28(8): 1974 - 1980. [Abstract] [Full Text] [PDF]

				R. Alemzadeh, T. Berhe, and D. T. Wyatt Flexible Insulin Therapy With Glargine Insulin Improved Glycemic Control and Reduced Severe Hypoglycemia Among Preschool-Aged Children With Type 1 Diabetes Mellitus Pediatrics, May 1, 2005; 115(5): 1320 - 1324. [Abstract] [Full Text] [PDF]

				Y. Han, M. E. Schneck, M. A. Bearse Jr, S. Barez, C. H. Jacobsen, N. P. Jewell, and A. J. Adams Formulation and Evaluation of a Predictive Model to Identify the Sites of Future Diabetic Retinopathy Invest. Ophthalmol. Vis. Sci., November 1, 2004; 45(11): 4106 - 4112. [Abstract] [Full Text] [PDF]

				V. Harjutsalo, S. Katoh, C. Sarti, N. Tajima, and J. Tuomilehto Population-Based Assessment of Familial Clustering of Diabetic Nephropathy in Type 1 Diabetes Diabetes, September 1, 2004; 53(9): 2449 - 2454. [Abstract] [Full Text] [PDF]

				M. Svensson, J. W. Eriksson, and G. Dahlquist Early Glycemic Control, Age at Onset, and Development of Microvascular Complications in Childhood-Onset Type 1 Diabetes: A population-based study in northern Sweden Diabetes Care, April 1, 2004; 27(4): 955 - 962. [Abstract] [Full Text] [PDF]

				J. T. Lane Microalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes mellitus: a temporal perspective Am J Physiol Renal Physiol, March 1, 2004; 286(3): F442 - F450. [Abstract] [Full Text] [PDF]

				H. P. Chase Glycemic Control in Prepubertal Years Diabetes Care, April 1, 2003; 26(4): 1304 - 1305. [Full Text] [PDF]

This Article Abstract Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Donaghue, K. C. Articles by Silink, M. Search for Related Content PubMed PubMed Citation Articles by Donaghue, K. C. Articles by Silink, M. Social Bookmarking                What's this?